• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?

作者信息

Porta Camillo, Cosmai Laura, Rizzo Mimma, Melazzini Mario

机构信息

Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.

Division of Translational Oncology, I.R.C.C.S. Istituti Clinici Scientifici Maugeri, Pavia, Italy.

出版信息

Ann Transl Med. 2019 Mar;7(Suppl 1):S15. doi: 10.21037/atm.2019.01.51.

DOI:10.21037/atm.2019.01.51
PMID:31032296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6462585/
Abstract
摘要

相似文献

1
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?血管生成相关基因中的单核苷酸多态性与肾细胞癌抗血管生成治疗的结果：这真的是迈向个性化肿瘤学的一步，还是并非如此？
Ann Transl Med. 2019 Mar;7(Suppl 1):S15. doi: 10.21037/atm.2019.01.51.
2
Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma.单核苷酸多态性作为肾细胞癌的预后和预测生物标志物
Oncotarget. 2017 Nov 20;8(63):106551-106564. doi: 10.18632/oncotarget.22533. eCollection 2017 Dec 5.
3
Pharmacogenomic biomarkers for personalized cancer treatment.用于癌症个体化治疗的药物基因组生物标志物。
J Intern Med. 2015 Feb;277(2):201-217. doi: 10.1111/joim.12321.
4
Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization.肾癌的药物基因组学与反应预测因子：迈向个体化治疗的步骤
Urol Oncol. 2015 Apr;33(4):179-86. doi: 10.1016/j.urolonc.2013.09.015. Epub 2014 Feb 1.
5
Antiangiogenic drugs for colorectal cancer: exploring new possibilities.结直肠癌的抗血管生成药物：探索新的可能性。
Clin Colorectal Cancer. 2013 Mar;12(1):1-7. doi: 10.1016/j.clcc.2012.06.002. Epub 2012 Jul 3.
6
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?肿瘤学中抗血管生成疗法发展的血管生成生物标志物：工具还是装饰？
Nat Clin Pract Oncol. 2008 Jul;5(7):378-91. doi: 10.1038/ncponc1150. Epub 2008 Jun 17.
7
Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models.抗血管生成化疗药物：与它们在人肾细胞癌模型中对肿瘤生长的抑制作用相比的特征
Clin Cancer Res. 1998 May;4(5):1331-6.
8
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.舒尼替尼或索拉非尼对接受过先前抗血管生成治疗的转移性肾细胞癌患者的抗肿瘤作用。
J Urol. 2008 Jan;179(1):81-6; discussion 86. doi: 10.1016/j.juro.2007.08.127. Epub 2007 Nov 12.
9
Commentary on "Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study." Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK, Dana-Farber Cancer Institute, Boston, MA 02115.: Lancet Oncol 2013;14(1):81-87. [Epub 2012 Dec 7]. doi: 10.1016/S1470-2045(12)70517-X. Erratum in, Lancet Oncol 2013;14(3):e89.《肾细胞癌复发风险与单核苷酸多态性：一项队列研究》述评。舒茨FA、波美兰茨MM、格雷KP、阿特金斯MB、罗森伯格JE、赫希MS、麦克德莫特DF、兰普龙ME、李GS、西尼奥雷蒂S、坎托夫PW、弗里德曼ML、乔埃里TK，达纳-法伯癌症研究所，马萨诸塞州波士顿02115。：《柳叶刀·肿瘤学》2013年；14(1)：81 - 87。[2012年12月7日在线发表]。doi: 10.1016/S1470 - 2045(12)70517 - X。勘误见《柳叶刀·肿瘤学》2013年；14(3)：e89。
Urol Oncol. 2014 May;32(4):512-3. doi: 10.1016/j.urolonc.2013.12.004.
10
Impact of polymorphisms in angiogenesis-related genes on clinical outcomes of radiotherapy in patients with nasopharyngeal carcinoma.
Clin Exp Pharmacol Physiol. 2017 May;44(5):539-548. doi: 10.1111/1440-1681.12738.

引用本文的文献

1
The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center.贝伐单抗联合化疗用于非鳞状非小细胞肺癌的最佳时机和疗程：来自中国一家癌症中心真实世界经验的启示
Ann Transl Med. 2020 Oct;8(20):1311. doi: 10.21037/atm-20-6327.

本文引用的文献

1
Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.辅助舒尼替尼治疗高危肾细胞癌的 III 期临床试验：探索性药物基因组学分析。
Clin Cancer Res. 2019 Feb 15;25(4):1165-1173. doi: 10.1158/1078-0432.CCR-18-1724. Epub 2018 Nov 6.
2
The search for gene-gene interactions in genome-wide association studies: challenges in abundance of methods, practical considerations, and biological interpretation.全基因组关联研究中基因-基因相互作用的探索：方法众多带来的挑战、实际考量及生物学解释
Ann Transl Med. 2018 Apr;6(8):157. doi: 10.21037/atm.2018.04.05.
3
Biomarker-guided antibiotic therapy-strengths and limitations.生物标志物引导的抗生素治疗——优势与局限
Ann Transl Med. 2017 May;5(10):208. doi: 10.21037/atm.2017.04.04.
4
Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.在接受舒尼替尼治疗的癌症患者中，整合药代动力学、药效学、药物遗传学和临床结局的群体建模。
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):604-613. doi: 10.1002/psp4.12210. Epub 2017 Jul 13.
5
Limits to Precision Cancer Medicine.精准癌症医学的局限性
N Engl J Med. 2017 Jan 5;376(1):96-7. doi: 10.1056/NEJMc1613563.
6
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.辅助舒尼替尼治疗肾切除术后高危肾细胞癌。
N Engl J Med. 2016 Dec 8;375(23):2246-2254. doi: 10.1056/NEJMoa1611406. Epub 2016 Oct 9.
7
Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.评估血管生成相关基因多态性作为舒尼替尼治疗转移性肾细胞癌患者的预测和预后标志物。
J Cancer Res Clin Oncol. 2016 Jun;142(6):1171-82. doi: 10.1007/s00432-016-2137-0. Epub 2016 Mar 3.
8
Kidney cancer: Single nucleotide polymorphisms in mRCC-is their time up?肾癌：转移性肾细胞癌中的单核苷酸多态性——它们的时代结束了吗？
Nat Rev Urol. 2015 Aug;12(8):424-6. doi: 10.1038/nrurol.2015.149. Epub 2015 Jun 30.
9
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.CYP3A5 和 ABCB1 多态性作为转移性肾细胞癌舒尼替尼疗效的预测因子。
Eur Urol. 2015 Oct;68(4):621-9. doi: 10.1016/j.eururo.2015.04.018. Epub 2015 Apr 27.
10
Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues.使用从福尔马林固定、石蜡包埋组织中提取的DNA进行单核苷酸和基于大小的DNA生物标志物评估的技术可重复性。
J Mol Diagn. 2015 May;17(3):242-50. doi: 10.1016/j.jmoldx.2014.12.001. Epub 2015 Mar 4.